Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES.

Michael SzarekEsther ReijndersPh Gabriel StegJ Wouter JukemaMarkus SchwertfegerDeepak L BhattVera A BittnerRafael DiazSergio FazioGenevieve GaronShaun G GoodmanRobert A HarringtonHarvey D WhiteAndreas M ZeiherChrista CobbaertGregory G Schwartz

Published in: European journal of preventive cardiology (2024)

Keyphrases

cardiovascular events
coronary artery disease
cardiovascular disease
low density lipoprotein
type diabetes
metabolic syndrome
clinical evaluation